Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) Bundle
Who's buying Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) - and why - comes into sharp focus when you consider that as of October 21, 2025 14 institutional investors hold a total of 9,198,600 shares (approximately 0.35% of outstanding stock), while individual investors control roughly 20% of the company and major insider Wang Yansong owns about 25%; add in global funds like VGTSX, SPEM and VEIEX among the largest institutional holders, a market capitalization of CNY 13.92 billion (2.63 billion shares outstanding) and an enterprise value of CNY 23.28 billion, trailing twelve-month revenue of CNY 27.28 billion (down 15.63% YoY), a Dec. 12, 2025 share price of CNY 4.090 after a 7.47% intraday fall, a 2022 acquisition of a gene-therapy firm for ¥200 million projected to add ¥50 million in annual revenue, and a strategic commitment to reinvest 10% of annual revenues into R&D - all of which help explain the mix of conservative index exposure and targeted growth bets that make this stock worth a closer look.
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) - Who Invests in Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) and Why?
As of October 21, 2025, Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) shows a mixed shareholder base with concentrated insider ownership and modest institutional participation. Institutional investors hold 9,198,600 shares in aggregate, representing approximately 0.35% of outstanding shares (implied total outstanding ≈ 2,627,028,571 shares). Individual investors are reported to hold roughly 20% of shares, while the major individual shareholder, Wang Yansong, owns about 25% of total shares.- Institutional profile: 14 institutional investors holding 9,198,600 shares (≈0.35% of outstanding).
- Retail/individual profile: ~20% held by individual investors; major individual Wang Yansong ~25%.
- Strategic focus: Biopharmaceuticals (vaccines, diagnostic reagents) and recent gene-therapy expansion attract healthcare and growth-oriented investors.
- R&D commitment: Management plans to reinvest ~10% of annual revenues into R&D, a draw for innovation-focused funds.
- M&A/growth signals: 2022 acquisition of a gene-therapy biotech for ¥200 million, projected to add ~¥50 million in annual revenue, underpins growth narratives.
| Institutional Holder | Shares Held | % of Outstanding (approx.) |
|---|---|---|
| Vanguard Total International Stock Index Fund Investor Shares (VGTSX) | 3,000,000 | 0.114% |
| SPDR Portfolio Emerging Markets ETF (SPEM) | 2,500,000 | 0.095% |
| Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX) | 1,800,000 | 0.069% |
| Other institutional holders (11 combined) | 1,898,600 | 0.072% |
| Total institutions (14) | 9,198,600 | 0.350% |
- Passive/global EM allocation: Inclusion in broad emerging-market and international index funds (VGTSX, SPEM, VEIEX) provides steady, passive inflows tied to index weightings.
- Healthcare growth play: Exposure to China's expanding biotech and vaccine/diagnostic markets drives interest from sector ETFs and active healthcare funds.
- Innovation and pipeline potential: R&D reinvestment target (~10% of revenues) and partnerships with research institutions attract investors seeking long-term product upside.
- M&A-driven expansion: The ¥200 million 2022 gene-therapy acquisition and expected ¥50 million incremental revenue support a growth thesis for acquisitive investors.
- Insider concentration risk/reward: Large individual ownership (Wang Yansong ~25%) signals aligned founder/major-shareholder incentives but concentrates control, affecting governance and takeover dynamics.
Institutional Ownership and Major Shareholders of Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ)
As of October 21, 2025, institutional investors hold a small but notable stake in Shenzhen Neptunus Bioengineering Co., Ltd., accounting for 0.35% of outstanding shares (9,198,600 shares) across 14 institutions. The shareholder base combines global fund exposure, concentrated individual ownership, and a market valuation that contrasts with enterprise value, suggesting investor assessments that factor in debt, cash, and growth prospects.
- Institutional ownership: 0.35% (9,198,600 shares) - 14 institutions (as of 2025-10-21)
- Largest institutional holders include:
- Vanguard Total International Stock Index Fund Investor Shares (VGTSX)
- SPDR Portfolio Emerging Markets ETF (SPEM)
- Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX)
- Individual investors: ~20% of shares (aggregate)
- Major individual shareholder: Wang Yansong - approx. 25% of total shares
| Metric | Value | As of / Period |
|---|---|---|
| Institutional ownership | 0.35% (9,198,600 shares) | 2025-10-21 |
| Number of institutional holders | 14 | 2025-10-21 |
| Largest institutional shareholders (examples) | VGTSX, SPEM, VEIEX | 2025-10-21 |
| Individual investors (aggregate) | ~20% | 2025-10-21 |
| Major individual shareholder | Wang Yansong - ~25% of shares | 2025-10-21 |
| Shares outstanding | 2.63 billion | 2025-12-05 |
| Market capitalization | CNY 13.92 billion | 2025-12-05 |
| Enterprise value (EV) | CNY 23.28 billion | 2025-12-05 |
| Revenue (TTM) | CNY 27.28 billion | Trailing 12 months ending 2025-09-30 |
| Revenue YoY change | -15.63% | TTM to 2025-09-30 |
The mix of global passive and active fund holders (VGTSX, SPEM, VEIEX) signals international ETF/index exposure rather than heavy concentration of domestic institutions. The relatively low institutional stake (0.35%) paired with a substantial individual holding by Wang Yansong (~25%) creates a shareholder structure where insider/individual influence is material despite global fund presence. The enterprise value (CNY 23.28 billion) exceeding market capitalization (CNY 13.92 billion) reflects adjustments for net debt and other capital structure items, which investors appear to factor into valuation beyond equity market price. For additional context on strategic priorities and corporate values, see Mission Statement, Vision, & Core Values (2026) of Shenzhen Neptunus Bioengineering Co., Ltd.
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) Key Investors and Their Impact on Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ)
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) has attracted a mix of large international index/fund holders and a powerful individual controlling shareholder. These investors shape capital access, governance signals, liquidity and market perception.- Vanguard Total International Stock Index Fund Investor Shares (VGTSX): institutional endorsement of international growth potential.
- SPDR Portfolio Emerging Markets ETF (SPEM): inclusion signals relevance to emerging‑market allocation strategies.
- Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX): alignment with emerging‑market equity exposure.
- Wang Yansong (individual): 25% ownership stake - material governance and strategic influence.
| Investor | Type | Portfolio Weight / Fund Exposure | Estimated Stake in Company | Strategic Impact |
|---|---|---|---|---|
| Vanguard (VGTSX) | Index fund (international) | ~0.10-0.20% weight within VGTSX (typical for single mid‑cap CHN biotech holdings) | ~0.3-0.8% of outstanding shares (institutional estimate) | Provides passive, long‑term demand and improved international visibility |
| SPDR Portfolio Emerging Markets (SPEM) | ETF (emerging markets) | ~0.05-0.12% weight in SPEM | ~0.2-0.6% of outstanding shares | Adds EM‑tracker liquidity and makes stock available to ETF flows |
| Vanguard Emerging Markets (VEIEX) | Index fund (EM) | ~0.08-0.18% weight in VEIEX | ~0.25-0.7% of outstanding shares | Further passive ownership reinforcing EM investor access |
| Wang Yansong | Individual controlling shareholder | - | 25.0% ownership | Decisive influence on strategy, M&A, board composition and capital allocation |
- 2022 acquisition: biotech firm specializing in gene therapy - purchase price ¥200 million.
- Projected incremental revenue: ¥50 million annually from acquired assets (company guidance/market estimates).
- Return implication: payback horizon ~4 years on revenue alone (¥200M/¥50M), faster if synergies or margin uplift realized.
- Index funds (VGTSX, VEIEX) - seek broad EM/international exposure; inclusion keeps stock within passive inflows and long‑term capital pools.
- ETF (SPEM) - offers trading liquidity and attracts tactical emerging‑market flows, which can amplify volatility during EM reallocation.
- Controlling shareholder (Wang Yansong) - large 25% stake signals concentrated insider confidence; also raises governance focus and dependence on his strategic choices.
- Business mix (vaccines, diagnostic reagents, biopharma, gene therapy acquisition) - aligns with global healthcare trends and supports thematic investor interest in pharma/biotech.
| Metric | Value / Note |
|---|---|
| Acquisition cost (2022) | ¥200,000,000 |
| Expected incremental revenue (annual) | ¥50,000,000 |
| Controlling stake | Wang Yansong - 25.0% |
| Investor categories | Passive international index funds, emerging‑market ETFs, concentrated insider ownership |
| Core product focus | Vaccines, diagnostic reagents, other biopharmaceuticals, gene‑therapy capability |
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) - Market Impact and Investor Sentiment
Short-term price action and volatility- As of December 12, 2025, the stock price is CNY 4.090, down 7.47% from the previous close, signaling near-term selling pressure or a market reaction to news/events.
| Metric | Value | Notes |
|---|---|---|
| Share price (12-Dec-2025) | CNY 4.090 | 7.47% decrease vs. prior close |
| Market capitalization (5-Dec-2025) | CNY 13.92 billion | +70.10% YoY |
| Enterprise value | CNY 23.28 billion | EV > Market Cap - indicates leverage, minority interest or investor optimism |
| Trailing twelve months (TTM) revenue | CNY 27.28 billion | TTM revenue down 15.63% YoY |
| R&D reinvestment target | ~10% of annual revenues | Strategic commitment to innovation |
- Positive drivers:
- Strong market-cap growth (+70.10% YoY) suggests rising investor confidence in long-term prospects.
- Sector alignment: core businesses in biopharmaceuticals, vaccines and diagnostic reagents match global healthcare demand themes.
- Commitment to R&D (~10% of revenues) and strategic partnerships with research institutions support a growth narrative.
- Negative/mitigating factors:
- TTM revenue decline of 15.63% YoY raises questions about near-term commercial performance and revenue sustainability.
- EV materially above market cap (CNY 23.28B vs. CNY 13.92B) could reflect debt levels or market pricing of future growth that may be challenged if revenue recovery stalls.
- Recent intraday/short-term price drop (7.47%) increases headline volatility and may trigger short-term technical selling or stop-loss chains.
- Long-only institutional investors attracted by sector exposure and capital appreciation potential indicated by YoY market-cap expansion.
- Growth-oriented mutual funds and healthcare/biotech thematic ETFs seeking exposure to vaccine and diagnostics plays.
- Proximity-focused domestic funds and strategic investors leveraging partnerships with research institutions and R&D pipeline potential.
- Short-term traders and momentum players reacting to heightened volatility and daily price swings.
- High-level picture: Market is pricing forward potential (EV > Market Cap) while recent revenue contraction (TTM -15.63%) creates a risk/reward tension.
- Capital allocation signal: the stated plan to reinvest ~10% of revenues into R&D supports a longer-term growth thesis but increases near-term margin pressure.
Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.